Company** | Product | Description | Indication | Type Action (Date) |
Name | ||||
CANCER | ||||
Anthra | AD32 | Lipophilic anthra- | Superficial bladder can- | Filed NDA (1/9) |
Pharmaceuticals | cycline analogue | cer in patients who have | ||
Inc.* | failed 1st-line therapy | |||
Chiron Corp. | Proleukin | Recombinant human | Single-agent therapy | Approved for marketing |
(FDA- | interleukin-2 | for metastatic melanoma | (1/12) | |
approved) | in adults (Stage IV) | |||
QLT PhotoThera- | Photofrin | Photosensitive drug | Treatment of microinva- | Approved for marketing |
peutics Inc. (Canada) | (FDA- | (produces toxic oxygen | sive endobronchial non- | (1/9) |
and Sanofi Pharma- | approved) | compound when light- | small cell lung cancer | |
ceuticals Inc. (unit | activated) | (early-stage) in patients | ||
of Sanofi SA; France) | who are not indicated for | |||
surgery and radiotherapy | ||||
CARDIOVASCULAR | ||||
Cor Therapeutics | Integrilin | Small molecule syn- | To reduce death, heart | FDA's Cardiovascular |
Inc. and Schering- | thetic compound | attack and other compli- | and Renal Drugs Adviso- | |
Plough Corp. | (derived from rattle- | cations of percutaneous | ry Committee recom- | |
(NYSE:SGP) | snake venom) that | transluminal coronary | mended approval in | |
inhibits GPIIb/IIIa | angioplasty as well as in | angioplasty setting but | ||
receptor that mediates | acute coronary condi- | recommended against | ||
platelet aggregation | tions (unstable angina | approval in acute syn- | ||
and non-Q-wave myo- | dromes (angina and non- | |||
cardial infarction [MI]) | Q-wave MI), stating that | |||
1 trial was not a suffi- | ||||
cient basis for approval in | ||||
the latter setting (1/28) | ||||
Texas | Novastan | Synthetic small mole- | Anticoagulant therapy in | FDA has extended its |
Biotechnology | cule (argatroban) deri- | patients with heparin- | review of NDA for up to | |
Corp. | ved from arginine; acts | induced thrombocyto- | 90 days in order to con- | |
as direct inhibitor of | penia | sider new data from a | ||
thrombin | follow-on study (1/23) | |||
DIABETES | ||||
Advanced Tissue | Dermagraft | Human tissue-engi- | Wound healing in | FDA's General and |
Sciences Inc. and | neered replacement for | diabetic foot ulcers | Plastic Surgery Devices | |
Smith & Nephew | dermal layer of skin | Advisory Committee | ||
plc (U.K.) | (viable human dermal | recommended approval | ||
fibroblasts cultured on | with condition that com- | |||
bioresorbable scaffold) | pany perform postmar- | |||
keting study and develop | ||||
physician training pro- | ||||
gram (7 to 2 vote) (1/29) | ||||
INFECTION | ||||
Unimed | NTZ | Nitazoxanide; a nitro- | Cryptosporidiosis in | Submitted NDA and |
Pharmaceuticals | thiazole compound with | AIDS patients (caused | requested priority review | |
Inc. (NASDAQ:UMED) | activity against many | by Cryptosporidium | (1/15) | |
protozoan and helmin- | parvum) | |||
thic pathogens | ||||
MISCELLANEOUS | ||||
Alexion | 5G1.1 | C5 complement inhib- | Systemic lupus | Filed IND (1/12) |
Pharmaceuticals | itor; humanized mono- | erythematosus | ||
Inc. | clonal antibody designed | |||
to inhibit complement | ||||
activation and reduce | ||||
inflammation over pro- | ||||
longed period of time | ||||
Bio-Technology | Androtab-SL | Sublingual delivery | Treatment of hypo- | FDA notified company |
General Corp. | (a.k.a. Andro- | system for testosterone | gonadism (testosterone | that data submitted with |
test-SL) | (produces pulse-like | deficiency) in males | NDA are inadequate for | |
increases in levels of | approval (1/28) | |||
hormone in blood) | ||||
CollaGenex | Periostat | Orally administered | Treatment of | FDA sent company a 2nd |
Pharmaceuticals | drug consisting of | periodontitis | action letter regarding | |
Inc. | sub-antibiotic dose of | NDA, stating that addi- | ||
doxycycline (inhibits | tional issues still need to | |||
production of | be addressed (1/28) | |||
collagenase) | ||||
Connetics Corp. | Betametha- | Foam formulation of | Treatment of all steroid- | Submitted NDA (1/6) |
sone mousse | corticosteroid betametha- | responsive dermatoses, | ||
sone-17-alpha valerate | including scalp psoriasis | |||
Epitope Inc. and | Cocaine | Enzyme immunoassay | Testing for drugs of | Cleared for marketing |
STC Technologies | metabolite | kit that detects cocaine | abuse | (1/15) |
Inc.* | EIA | and cocaine metabolites | ||
in oral fluids (collected | ||||
with Epitope's OraSure | ||||
oral specimen collection | ||||
device) | ||||
GelTex | RenaGel | Non-absorbed polymer- | Control of elevated | FDA accepted NDA for |
Pharmaceuticals | based compound that | phosphorus levels in | filing (1/5) | |
Inc. and | binds to and eliminates | chronic kidney failure | ||
Genzyme Corp. | target substances from | (administered in con- | ||
the intestinal tract | junction with dietary | |||
calcium supplement) | ||||
Organogenesis | Apligraf | Living human-skin | Treatment of venous | FDA's General and Plas- |
Inc. and Novartis | (a.k.a. | equivalent, composed of | leg ulcers | tic Surgery Devices Ad- |
Pharma AG | Graftskin) | living human keratino- | visory Committee recom- | |
(Switzerland) | cytes and fibroblasts | mended approval (5 to 4 | ||
(epidermis and dermis) | vote) (1/29) | |||
cultured in a 3-dimen- | ||||
sional culture system | ||||
SangStat Medical | Thymo- | Rabbit anti-human | Treatment and preven- | FDA sent companies a |
Corp. and the Imtix | globulin | thymocyte polyclonal | tion of acute graft rejec- | "complete review" letter |
division of Pasteur | antibody | tion episodes in kidney | regarding the PLA (1/28) | |
Merieux Connaught | transplant patients | |||
(member of the Rhone- | ||||
Poulenc Group; France) | ||||
Sheffield | — | Albuterol sulfate | Asthma | Filed IND (1/6) |
Pharmaceuticals | delivered via Metered | |||
Inc. | Solution Inhaler | |||
NOTES: | ||||
Not all the companies represented in this chart are biotechnology firms. Large pharmaceutical companies are included from time to time when the products they are developing address overwhelmingly important diseases such as AIDS and cancer, and where biotech companies are developing competing products. | ||||
* Private companies are indicated with an asterisk. | ||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 10-11. |